Charles H. Hennekens
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Charles H. Hennekens has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Patricia R. Hebert
Florida Atlantic University, Boca Raton, FL 33431, USA
5 shared publicationsWendy R. Schneider
Florida Atlantic University, Boca Raton, FL, USA
5 shared publicationsDavid DeMets
3 shared publicationsE. Joan Barice
Charles E. Schmidt College of Medicine, Florida Atlantic University, Boca Raton, FL, USA
3 shared publications- Ann T. MacIntyre
Private Practice, Miami, Florida
2 shared publications Marc A. Pfeffer
Division of Cardiovascular Medicine, Harvard Medical School, Brigham and Women's Hospital, Boston, Mass
2 shared publications
Latest Publications
- 1 May 2017
- Published by Elsevier in The American Journal of Medicine
- Vol. 130 (5) , 504-506
Statins and Diabetes: Current Perspectives and Implications for Clinicians
- 1 May 2017
- Published by Elsevier in The American Journal of Medicine
- Vol. 130 (5) , 504-506
Statins and Diabetes: Current Perspectives and Implications for Clinicians
- 8 February 2016
- Published by Walter de Gruyter GmbH
- p. 155-178
9. Statins in the treatment and prevention of cardiovascular diseases
- 8 February 2016
- Published by Walter de Gruyter GmbH
- p. 155-178
9. Statins in the treatment and prevention of cardiovascular diseases
- 1 May 2015
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 25 (4) , 348-350
Guidelines and guidance in lipid modification
- 1 May 2015
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 25 (4) , 348-350
Guidelines and guidance in lipid modification
- 1 December 2014
- Published by Elsevier in The American Journal of Medicine
- Vol. 127 (12) , 1142-1143
Increasing Rates of Advance Care Planning Through Interdisciplinary Collaboration
- 1 December 2014
- Published by Elsevier in The American Journal of Medicine
- Vol. 127 (12) , 1142-1143
Increasing Rates of Advance Care Planning Through Interdisciplinary Collaboration
- 1 November 2014
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 24 (8) , 360-366
Aspirin in the primary prevention of cardiovascular disease: Current knowledge and future research needs
- 1 November 2014
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 24 (8) , 360-366
Aspirin in the primary prevention of cardiovascular disease: Current knowledge and future research needs
- 7 August 2014
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 20 (1) , 9-10
Calcium and Vitamin D Supplementation
- 7 August 2014
- Published by SAGE Publications in Journal of Cardiovascular Pharmacology and Therapeutics
- Vol. 20 (1) , 9-10
Calcium and Vitamin D Supplementation
- 8 February 2014
- Published by S. Karger AG in Cardiology
- Vol. 128 (1) , 41-42
Utilization of Statins: Guiding Principles and the New United States Guidelines
Despite remarkable declines in mortality, cardiovascular disease (CVD) will remain the major cause of premature death in the United States and is becoming the major cause of premature deaths worldwide [1]. The small-to-moderate net benefits of statins in the treatment and prevention of CVD are statistically significant and clinically important for this common and serious disease [2]. There is a large, robust, and consistent totality of evidence that includes cogent findings from basic research, descriptive and observational analytic epidemiological studies as well as large-scale randomized trials [3]. For the reliable detection of small-to-moderate effects, randomized evidence is crucial because the amount of uncontrolled and uncontrollable confounding inherent in all nonrandomized design strategies may be as big as the effect sizes [4]. Randomized evidence is necessary to develop guidelines which have recently been revised and widely disseminated throughout the USA [5]. We believe that such guidelines are necessary but not sufficient for astute clinical judgments. In this manuscript we prefer general guiding principles to further aid the clinician to making the best individual judgment after weighing the benefits and risks of a statin in light of the entire risk profile of the patient. The benefits and risks of statins have recently been updated in comprehensive worldwide meta-analyses of large-scale randomized trials designed a priori to test the hypothesis in secondary prevention patients as well as high-risk primary prevention subjects [6].
- 8 February 2014
- Published by S. Karger AG in Cardiology
- Vol. 128 (1) , 41-42
Utilization of Statins: Guiding Principles and the New United States Guidelines
Despite remarkable declines in mortality, cardiovascular disease (CVD) will remain the major cause of premature death in the United States and is becoming the major cause of premature deaths worldwide [1]. The small-to-moderate net benefits of statins in the treatment and prevention of CVD are statistically significant and clinically important for this common and serious disease [2]. There is a large, robust, and consistent totality of evidence that includes cogent findings from basic research, descriptive and observational analytic epidemiological studies as well as large-scale randomized trials [3]. For the reliable detection of small-to-moderate effects, randomized evidence is crucial because the amount of uncontrolled and uncontrollable confounding inherent in all nonrandomized design strategies may be as big as the effect sizes [4]. Randomized evidence is necessary to develop guidelines which have recently been revised and widely disseminated throughout the USA [5]. We believe that such guidelines are necessary but not sufficient for astute clinical judgments. In this manuscript we prefer general guiding principles to further aid the clinician to making the best individual judgment after weighing the benefits and risks of a statin in light of the entire risk profile of the patient. The benefits and risks of statins have recently been updated in comprehensive worldwide meta-analyses of large-scale randomized trials designed a priori to test the hypothesis in secondary prevention patients as well as high-risk primary prevention subjects [6].
- 1 January 2013
- Published by Elsevier in The American Journal of Medicine
- Vol. 126 (1) , 76-80
United States Counties with Low Black Male Mortality Rates
- 1 January 2013
- Published by Elsevier in The American Journal of Medicine
- Vol. 126 (1) , 76-80
United States Counties with Low Black Male Mortality Rates
- 28 February 2012
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 9 (5) , 262-263
Aspirin in primary prevention—good news and bad news
The balance of benefits and risks of aspirin in primary prevention is far less clear than in secondary prevention; further data from randomized trials of individuals at intermediate cardiovascular risk are needed. Decisions about aspirin in primary prevention should be made on a case-by-case basis, and general guidelines are not justified.
- 28 February 2012
- Published by Springer Nature in Nature Reviews Cardiology
- Vol. 9 (5) , 262-263
Aspirin in primary prevention—good news and bad news
The balance of benefits and risks of aspirin in primary prevention is far less clear than in secondary prevention; further data from randomized trials of individuals at intermediate cardiovascular risk are needed. Decisions about aspirin in primary prevention should be made on a case-by-case basis, and general guidelines are not justified.
- 1 January 2012
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 58 (1) , 303-304
Aspirin in the Primary Prevention of Myocardial Infarction
Featured Article: Steering Committee of the Physicians' Health Study Research Group: Belanger C, Buring JE, Cook N, Eberlein K, Goldhaber SZ, Gordon D, et al. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129–35.4 In 1897, Felix Hoffman, a chemist working at Bayer in Elberfeld, Germany, synthesized the first stable form of acetylsalicylic acid. He was motivated, in part, to help his father, who suffered from painful and disabling arthritis. In the 20th century, acetylsalicylic acid, under its trade name, aspirin, became the most widely used drug in the world, but not until 1971 did Sir John Vane elucidate a new and novel mechanism of aspirin to irreversibly inhibit platelet aggregation. In 1982, Vane was awarded the Nobel Prize in physiology or medicine, but the role of aspirin in the prevention of a first myocardial infarction (MI)5 was yet to be discovered. In 1982, the Physicians' Health Study (PHS) was funded by the US NIH as an investigator-initiated research grant. The PHS randomized 22 071 dedicated and conscientious male physicians at low risk of a first cardiovascular disease (CVD) event. On December 18, 1987, the independent Data and Safety Monitoring Board of the PHS unanimously recommended the early termination of the aspirin component, primarily because of the emergence of a statistically …
- 1 January 2012
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 58 (1) , 303-304
Aspirin in the Primary Prevention of Myocardial Infarction
Featured Article: Steering Committee of the Physicians' Health Study Research Group: Belanger C, Buring JE, Cook N, Eberlein K, Goldhaber SZ, Gordon D, et al. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129–35.4 In 1897, Felix Hoffman, a chemist working at Bayer in Elberfeld, Germany, synthesized the first stable form of acetylsalicylic acid. He was motivated, in part, to help his father, who suffered from painful and disabling arthritis. In the 20th century, acetylsalicylic acid, under its trade name, aspirin, became the most widely used drug in the world, but not until 1971 did Sir John Vane elucidate a new and novel mechanism of aspirin to irreversibly inhibit platelet aggregation. In 1982, Vane was awarded the Nobel Prize in physiology or medicine, but the role of aspirin in the prevention of a first myocardial infarction (MI)5 was yet to be discovered. In 1982, the Physicians' Health Study (PHS) was funded by the US NIH as an investigator-initiated research grant. The PHS randomized 22 071 dedicated and conscientious male physicians at low risk of a first cardiovascular disease (CVD) event. On December 18, 1987, the independent Data and Safety Monitoring Board of the PHS unanimously recommended the early termination of the aspirin component, primarily because of the emergence of a statistically …